Advertisement

Cell Biophysics

, Volume 21, Issue 1–3, pp 25–31 | Cite as

The p53 tumor suppressor gene

A preliminary clinical study in breast cancer patients
  • G. Micelli
  • A. Donadeo
  • M. Quaranta
Article

Abstract

p53 was originally considered to be a nuclear oncogene, but several convergent lines of research have indicated that the wild-type gene functions as a tumor suppressor gene negatively regulating the cell cycle. Mutations in the p53 gene have been detected in many tumor types and seem to be the most common genetic alterations in human cancer. In this preliminary study, sera of 92 patients (pts) with breast disease were analyzed for the presence of the mutant p53 protein (mp53) with a selective immunoenzyme assay employing a monoclonal antibody (PAb 240) specific for the majority of mammalian m p53 but not for the wild-type protein. Of the 10 patients with benign breast disease, only two (20%) showed detectable m p53 levels in the serum. In the breast cancer group, sera from 7 of the 30 pts (23%) without lymph node involvement were positive for m p53, as were 7 out of the 45 pts (15%) with metastatic lymph nodes and 1 out of the 7 pts (14%) with disseminated disease. The specifity of m p53 assay evaluated in 20 healthy controls was 100%. These preliminary results showed that serum positivity for m p53 is not related to breast disease extension. Further studies to assess the utility of m p53 as a possible prognosis factor in breast cancer are currently in progress.

Keywords

Breast Cancer Breast Disease Benign Breast Disease Breast Cancer Group Breast Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fisher, B., Bauer, M., Wickerham, D. L., Redmond, C. K., and Fisher, E. R. (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer.Cancer,52, 1551–1557.PubMedCrossRefGoogle Scholar
  2. 2.
    McGuire, W. L., Clark, G. M., Dressler, L. G., and Owens, M. A. (1986) Role of steroid hormone receptors as prognostic factors in primary breast cancer.N. C. I. Monogr. 1, 19–23.Google Scholar
  3. 3.
    Bloom, H. J. G. and Field, J. R. (1971) Impact on tumor grade and host resistance on survival of women with breast cancer.Cancer 50, 1580–1589.CrossRefGoogle Scholar
  4. 4.
    Ellis, C. N., Frey, E. S., Burnette, J. J., Akin, J. M., Jr. Reading, C., Gaskin, T. A., and Blakemore W. S. (1989) The content of tumor DNA as an indicator of prognosis in patients with T1NOMO carcinoma of the breast.J. Surgery 106, 133–138.Google Scholar
  5. 5.
    Winchester, D. J., Duda, R. B., August, C. Z., Goldschmidt, R. A., Wruck, D. M., Rademaker, A. W., Winchester, D. P., and Merkel, D. E. (1990) The importance of DNA flow cytometry in node-negative breast cancer.Arch. Surg. 125, 886–889.PubMedGoogle Scholar
  6. 6.
    Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 235, 177–182.PubMedCrossRefGoogle Scholar
  7. 7.
    Lane, D. P. and Crawford, L. V. (1979) Tantigen is bound to a host protein in SV40-transformed cells.Nature 278, 261–263.PubMedCrossRefGoogle Scholar
  8. 8.
    Milner, J. and Watson, J. V. (1990) Addition of fresh medium induces cell cycle and conformation changes in p53, a tumor suppressor protein.Oncogene 5, 1683–1690.PubMedGoogle Scholar
  9. 9.
    Reich, N. C. and Levine, A. J. (1984) Growth regulation of a cellular tumour antigene, p53, in nontransformed cells.Nature 308, 199–201.PubMedCrossRefGoogle Scholar
  10. 10.
    Steinmeyer, K., Maacke, H., and Deppert, W. (1990) Cell cycle control by p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. Regulation of p53 expression.Oncogene 5, 1691–1699.PubMedGoogle Scholar
  11. 11.
    Mercer, W. E., Avignolo, C., and Baserga, R. (1984) Role of the p53 protein in cell proliferation as studies by microinjection of monoclonal antibodies.Mol. Cell. Biol. 4, 276–284.PubMedGoogle Scholar
  12. 12.
    Shohat, O., Greenberg, M., Reisman, D., Oren, M., and Rotter, V. (1987) Inhibition of cell growth mediated by plasmids encoding p53 anti-sense.Oncogene 1, 277–283.PubMedGoogle Scholar
  13. 13.
    Eliyahu, D., Raz, A., Gruss, P., Givol, D., and Oren, M. (1984) Participation of p53 cellular tumour antigen in transformation of normal embryonic cells.Nature 312, 646–649.PubMedCrossRefGoogle Scholar
  14. 14.
    Jenkins, J. R., Rudge, K., Chumakov, P., and Currie, G. A. (1985) The cellular oncogene p53 can be activated by mutagenesis.Nature 317, 816–818.PubMedCrossRefGoogle Scholar
  15. 15.
    Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., and Rotter, V. (1984) Cooperation between gene encoding p53 tumour antigen andras in cellular transformation.Nature 312, 649–651.PubMedCrossRefGoogle Scholar
  16. 16.
    Hinds, P., Finlay, C., and Levine, A. J. (1989) Mutation is required to activate the p53 gene for cooperation with theras oncogene and transformation.J. Virol. 63, 739–746.PubMedGoogle Scholar
  17. 17.
    Hinds, P., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., and Levin, A. J. (1990) Mutant p53 DNA clones from human colon carcinomas cooperate withras in transforming primary rat cells: a comparison of the “hot-spot” mutant phenotypes.Cell Growth Differ,1, 569–576.Google Scholar
  18. 18.
    Eliyahu, D., Machalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. (1989) Wid-type p53 can inhibit oncogen-mediated focus formation.Proc. Natl. Acad. Sci. USA,86, 8763–8767.PubMedCrossRefGoogle Scholar
  19. 19.
    Finlay, C. A., Hinds, P. W., and Levine, A. J. (1989) The p53 protooncogene can act as a suppressor of transformation.Cell 57, 1083–1093.PubMedCrossRefGoogle Scholar
  20. 20.
    Davidoff, A. M., Humphrey, P. A., Iglehart, J. D., and Marks, J. R. (1991) Genetic basis for p53 overexpression in human breast cancer.Proc. Natl. Acad. Sci. USA 188, 5006–5040.CrossRefGoogle Scholar
  21. 21.
    James, C. D., Carlbom, E., Nordenskjold, M., Collins, V. P., and Cavanee, W. K. (1989) Mitotic recombination of chromosomes 17 in astrocytomas.Proc. Natl. Acad. Sci. USA 86, 2858–2862.PubMedCrossRefGoogle Scholar
  22. 22.
    Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. L. (1990) Increased expression of mutant forms of p53 oncogene in primary lung cancer.Lancet 335, 675–679.PubMedCrossRefGoogle Scholar
  23. 23.
    Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., and Minna, J. D. (1989) p53: a frequent target for genetic abnormalities in lung cancer.Science 246, 491–494.PubMedCrossRefGoogle Scholar
  24. 24.
    Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura Y., White, R., and Vogelstein, B. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.Science 244, 217–221.PubMedCrossRefGoogle Scholar
  25. 25.
    Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modal, R., Harris, C. C., and Vogelstein, B. (1989) Mutations in the p53 gene occur in diverse human tumour types.Nature 342, 705–708.PubMedCrossRefGoogle Scholar
  26. 26.
    Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L., and Delia, D. (1988) p53 expression in breast cancer.Int. J. Cancer 41, 178–183.PubMedCrossRefGoogle Scholar
  27. 27.
    Gannon, J. V., Greaves, R., Iggo, R., and Lane, D. P. (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.EMBO J. 9, 1595–1602.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 1993

Authors and Affiliations

  • G. Micelli
    • 1
  • A. Donadeo
    • 1
  • M. Quaranta
    • 1
  1. 1.Clinical-Chemistry LaboratoryOncology InstituteBariItaly

Personalised recommendations